Evidence map›Paper›PMID 41491289›Full record

ArticleThe pharmacogenomics journal2026

Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients.

Anna Tsironi, Effrosyni Mendrinou, Stavroula Siamoglou, Kyriaki Kydonopoulou, Anne John, Alexandra Gerou, Spyridon Gerou, Bassam R Ali, Marios Papasotiriou, George P Patrinos

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anna TsironiDepartment of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, University of Patras School of Health Sciences, Patras, Greece.ORCID 0009-0003-2499-0707
Effrosyni MendrinouMolecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, Greece.ORCID 0000-0002-8753-857X
Stavroula SiamoglouDepartment of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, University of Patras School of Health Sciences, Patras, Greece.
Kyriaki KydonopoulouANALYSI S.A., Thessaloniki, Greece.
Anne JohnCollege of Medicine and Health Sciences, Department of Genetics and Genomics, United Arab Emirates University, Al-Ain, Abu Dhabi, UAE.
Alexandra GerouANALYSI S.A., Thessaloniki, Greece.
Spyridon GerouANALYSI S.A., Thessaloniki, Greece.
Bassam R AliCollege of Medicine and Health Sciences, Department of Genetics and Genomics, United Arab Emirates University, Al-Ain, Abu Dhabi, UAE.ORCID 0000-0003-1306-6618
Marios PapasotiriouDepartment of Nephrology and Kidney Transplantation, University Hospital of Patras, Patras, Greece.ORCID 0000-0001-9375-989X
George P PatrinosDepartment of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, University of Patras School of Health Sciences, Patras, Greece. gpatrinos@upatras.gr.ORCID 0000-0002-0519-7776

Funding

European Commission (EC) 668353
6 · The paper itself

Abstract

Tacrolimus, a calcineurin inhibitor with a narrow therapeutic index, requires precise dosing to optimize efficacy and minimize adverse effects in kidney transplant recipients. Although CYP3A5 genetic variants influence tacrolimus pharmacokinetics, they do not fully explain inter-individual differences. This retrospective study evaluated the combined impact of CYP3A4 [*1B (rs2740574), *1 G (rs2242480), *22 (rs35599367)] and CYP3A5 [*3 (rs776746), *6 (rs10264272), *7 (rs41303343)] genetic variants, as CYP3A phenotypes, on tacrolimus dose-adjusted trough concentrations (C

Indexed as

Cytochrome P-450 CYP3AImmunosuppressive AgentsKidney TransplantationTacrolimusAdultAgedCalcineurin InhibitorsDose-Response Relationship, DrugFemaleGenetic VariationHumansMaleMiddle AgedPolymorphism, Single NucleotideRetrospective StudiesCalcineurin InhibitorsCYP3A4 protein, humanCYP3A5 protein, humanCytochrome P-450 CYP3AImmunosuppressive AgentsTacrolimus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.